Compare the efficacy and safety of two combination regimens of miltefosine and paromomycin with the current standard treatment
current phase of drug development
updated 1 Mar 2022
Based on the good efficacy of the miltefosine and paromomycin (MF+PM) combination therapy in South Asia, and on the need for an alternative and safer treatment to replace sodium stibogluconate, a Phase III study was launched in 2018 to compare a combination regimens of miltefosine and paromomycin against the current standard visceral leishmaniasis treatment, sodium stibogluconate and paromomycin.
If this new combination is proven safe and effective, treatment would no longer rely on sodium stibogluconate, an injectable drug with potential toxic side effects, but would be replaced with miltefosine, an oral drug. A safer, more field-adapted, patient-friendly treatment would particularly benefit children, who represent a high proportion of the population at risk in East Africa.
News & resources
- 31 October 2022 - New treatment for kala-azar spells renewed hope for patients, People Daily
- 17 October 2022 - Kala-azar: There is now better, shorter treatment, The Standard
- 10 October 2022 - Drug combination offers shorter, more effective visceral leishmaniasis treatment, Nature Africa
- 10 October 2022 - The world versus leishmaniasis, The Medicine Maker
- 7 October 2022 - Leishmaniasis: New drug works quicker and with less pain, BBC
- 3 October 2022 - DNDi 2022 Projects of the Year recognize partners and colleagues for their work in developing new treatments for leishmaniasis
- 30 September 2022 - New, combined treatment for VL patients becomes effective in East Africa, Ethiopian Herald
- 30 September 2022 - Hope for kala-azar patients as new treatment is discovered, Nation
- 29 September 2022 - New treatment for visceral leishamaniasis effective – study says, Science Africa
- 29 September 2022 - New leishmaniasis treatment shows effectiveness in Eastern Africa, New Business Ethiopia
- 29 September 2022 - Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa
- 29 September 2022 - The Science Explained: Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa
- 27 September 2022 - Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial, Clinical Infectious Diseases
- 13 April 2018 - Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
Get our latest news, personal stories, research articles, and job opportunities.